The study of the efficiency and the safety of keigairengyoto(TJ-50) on acne vulgaris

INTERVENTION: Group A: The treatment with medicine for external use (Adapalen and Nadifloxacine or Clindamycine) for 12 weeks Group B: The treatment with medicine for external use (Adapalen and Nadifloxacine or Clindamycine) with Oral Administration of keigairengyoto (2.5g t.i.d before meals) for 12 weeks CONDITION: Acne vulgaris PRIMARY OUTCOME: *The decrement of inflammatory of acne lesions; *The decrement of non‐inflammatory of acne lesions; *Skindex‐16; *Patients satisfaction(Visual analog scale) INCLUSION CRITERIA: 1) Patients who have inflammatory of acne lesions on their faces 2) Patients for whom oral administration was possible 3) Patients who agreed with their written informed consent